Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib with carboplatin and paclitaxel in BRCA-mutated or TNBC
NCT02358200Phase 1Terminated
- Sponsor
- Alessa Therapeutics
- Start
- Feb 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in triple negative breast cancer (TNBC) and solid tumor, sponsored by Alessa Therapeutics. Started Feb 2015; status: terminated.
02
Drugs
talazoparib
03
Conditions
triple negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on NCT02358200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358200.